Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mcdougall, C.
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Prevention of diabetes in cardiovascular studies: implications for the aetiology of type 2 diabetes

Claire Mcdougall

Miles Fisher

Wards 10 & 11, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0SF, miles.fisher{at}northglasgow.scot.nhs.uk

Recent studies have shown the importance of lifestyle measures in preventing or delaying the development of type 2 diabetes in people with impaired glucose tolerance (IGT). Lifestyle measures appear to be more beneficial than therapy with metformin, or acarbose, and the benefit is most likely to be mediated by reductions in insulin resistance. Several large, multi-centre cardiovascular studies have also been performed where the development of new diabetes has been a secondary end point, and some ACE inhibitors, angiotensin receptor antagonists, and statins also appear to prevent or delay the development of diabetes in at-risk patients. These may act by increasing insulin sensitivity, decreasing inflammatory markers, or by affecting other key components of the metabolic syndrome. This is being tested in ongoing studies in patients with IGT.

Key Words: diabetes • cardiovascular disease • insulin resistance • ACE inhibitors • angiotensin receptor antagonists • statins.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 5, 384-389 (2002)
DOI: 10.1177/14746514020020050701
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?